Résumé
INTRODUCTION: GUARD (vildaGliptin clinical Use in reAl woRlD) was a multinational, prospective, observational study that assessed the effectiveness,safety and tolerability of vildagliptin and vildagliptin+metformin in patients with type 2 diabetes mellitus (T2DM) under real-world conditions across four geographical regions (Asia, the Middle East, Central America and Africa). The current paper discusses the results of patients with T2DM enrolled in the Philippines.METHODS: Patients with T2DM who were prescribed vildagliptin or vildagliptin+metformin combination therapy were enrolled and followed as per routine clinical practice for 24 ± six weeks. Primary endpoint was the change in HbA1c from baseline to study end (week 24±6). Key secondary endpoints included proportion of patients reaching target HbA1c ?7.0%, incidence of hypoglycemic events, adverse events (AEs) and serious AEs (SAEs).RESULTS: A total of 1,117 patients were included in the final analysis, 280 on vildagliptin (of these, eight patients received additional oral antidiabetes medications) and 837 on vildagliptin+metformin. At baseline, the mean (±SD) age of the enrolled population was 54.1±11.5 years, BMI 26.3±4.7 kg/m2, HbA1c 8.0±1.2% and T2DM duration 2.3±4.0 years.At study end, significant mean (±SE) reductions in HbA1c of -1.2±0.1% (pCONCLUSION: Vildagliptin and vildagliptin+metformin significantly reduced HbA1c with good weight control and low incidence of hypoglycemia in patients with T2DM under real-world conditions in Philippines